
ARTV Stock Forecast & Price Target
ARTV Analyst Ratings
Bulls say
Artiva Biotherapeutics Inc is advancing a promising pipeline of allogeneic NK cell therapies, with positive enrollment trends suggesting strong investor interest and confidence in the product’s safety and efficacy. The company’s bull case forecasts a significant increase in the probability of success (POS) for its AlloNK candidate, with the potential for substantial upside as new clinical data is expected to emerge. Notably, Artiva’s current market valuation shows a modest premium based on anticipated cash projections, indicating room for potential appreciation as the company progresses in its clinical trials and continues to receive regulatory support.
Bears say
Artiva Biotherapeutics Inc exhibits a negative outlook primarily due to the inherent risk associated with its lead candidate, AlloNK, which faces the potential for an unfavorable initial clinical data release in 1H:25, indicating its inability to achieve deep B-cell aplasia or tolerance issues. This scenario could dramatically lower the probability of success (POS) for the product to as low as 10%, suggesting a downside of approximately 25% from the base case projections. Additionally, the company's overall performance is undermined by concerns regarding the viability of its NK cell therapy platform to generate further successful clinical candidates, thereby increasing uncertainty surrounding its future growth and financial stability.
This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ARTV Analyst Forecast & Price Prediction
Start investing in ARTV
Order type
Buy in
Order amount
Est. shares
0 shares